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hours. Plasma aldosterone was 14.2 ng/dl at baseline, 4.5 ng/dl at 30
minutes after injection of the renin inhibitor, and 11.6 ng/dl at 24 hours.
At the end of the study, the patient was treated with enalapril and
hydrochlorothiazide.
Discussion
Case presentation
A 42-year-old black man with a history of essential hypertension was
admitted to the Clinical Research Center at the Boston University
School of Medicine for participation in a research protocol designed to
assess the blood-pressure-lowering effect of the renin inhibitor A-64662
(Abbott Laboratories). He had not taken his previous antihypertensive
medication for 3 weeks, and he was in good general health. On
admission, the blood pressure was 174/108 mm Hg; the physical
examination was otherwise unremarkable. Routine laboratory studies,
including renal function tests and urinalysis, were normal. On the
second day of hospitalization, and following an overnight fast, the
patient received as per protocol an intravenous injection of 0.7 mg/kg of
the renin inhibitor while blood pressure was monitored continuously.
Baseline blood pressure was 166/104 mm Hg and remained virtually
unchanged throughout the 3-hour duration of the study, except for a
slight decrease between 95 and 135 minutes. The observed maximal
decrease in mean blood pressure was 4 mm Hg and occurred at 105
minutes. At the end of the 3-hour period, he received a 50 mg tablet of
the angiotensin-converting-enzyme (ACE) inhibitor captopril. After 30
minutes, his blood pressure was 146/96 mm Hg; it reached its nadir of
138/94 mm Hg at 60 minutes, gradually increasing towards baseline
thereafter. The maximal drop in the mean blood pressure after captopril
admininistration was 17 mm Hg (Table 1). Blood pressure was 164/104
mm Hg at 24 hours.
Plasma renin activity (PRA) was 0.7 ng/ml/hr at baseline and fell to
undetectable levels (less than 0.05 ng/ml/hr) 30 minutes after injection of
the renin inhibitor; PRA returned to 0.15 ng/ml/hr at 24 hours. Baseline
plasma angiotensin II was 3.6 pg/mI, declining to 0.9 pg/mI 30 minutes
after injection of the renin inhibitor and returning to 2.4 pglml at 24
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DR. IRENE GAVRAS (Clinical Professor of Medicine, Boston
University School of Medicine; Attending Physician, University
Hospital; and Assistant Visiting Physician, Boston City Hospi-
tal, Boston, Massachusetts): This patient had low-renin essen-
tial hypertension that failed to respond to effective renin inhi-
bition but did respond partially to acute ACE inhibition.
Documentation of the effectiveness of renin inhibition was
obtained by concurrent measurements of plasma levels of
angiotensin II and aldosterone, both of which decreased con-
currently with suppression of renin activity and both of which
subsequently rose in parallel with the cessation of renin sup-
pression; by 24 hours, all three levels had returned toward
baseline.
Yet despite effectively inhibiting angiotensin II formation,
infusion of the renin inhibitor had virtually no effect on the
blood pressure in this patient, whereas subsequent ACE inhi-
bition elicited a significant response. This finding suggests that
angiotensin Il-dependent vasoconstriction was not the crucial
mechanism sustaining his high blood pressure and that ACE
inhibition must have acted through a mechanism other than the
elimination of angiotensin II. The most obvious candidate for
such a mechanism is the potentiation of bradykinin.
Bradykinin was first described by Rocha e Silva et al in 1920
as a substance that induces a slow motility of intestinal seg-
ments—hence its name [11. The nonapeptide bradykinin and the
decapeptide kallidin (LYS-bradykinin) are the main peptides
derived from proteolysis of the inactive precursor kininogen by
the action of tissue and plasma enzymes, collectively known as
kininogenases. The best-known and most potent kininogenases
are glandular or tissue kallikrein (the kallikrein relevant to all
subsequent discussion herein) and a completely different en-
zyme, called plasma kallikrein. Tissue kallikrein, found in
brain, heart, kidneys, and the vascular wall of arteries and
veins, generates kinins locally. The chemical structures of both
bradykinin and kallidin were elucidated 30 years ago; both have
similar pharmacologic properties with minor quantitative differ-
ences. These substances are further metabolized by several
peptidases in tissues and body fluids, most notably kininase II,
which is particularly concentrated in the pulmonary circulation,
and neutral endopeptidase 24.11, which is the main kininase in
the kidney {21. Figure 1 schematically depicts the generation of
bradykinin from its substrate via the action of kallikrein, and
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Table 1. Clinica! and biochemical parameters fol lowing renin inhibition and ACE inhibition
Control
30 mm
post veh
Renin inhibition ACE inhibition
60 mm post
captopril
Recovery
24 hr
30 mm
post drug
120 mm
post drug
BP, mm Hga
PRA, ng/ml/hr
All, pg/mi
Aldo,ng/dl
166/104
0.7
3.6
14.2
164/102
<0.05
0.9
4.5
164/104
<0.05
1.1
5.4
138/94
—
—
—
164/104
0.15
2.4
11.6
a BP, blood pressure; PRA, plasma renin activity; All, angiotensin II (in plasma); Aldo, aldosterone (in plasma); veh, vehicle for renin inhibitor;
drug, renin inhibitor.
X-Arg-Met-Lys-Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg-Ser-Val-X
(kininogen)
kallikrein
Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg
(bradykinin)
Kininase II
Angiotensin-converting enzyme
Arg-Pro-Pro-Gly-Phe-Ser-Pro
(inactive heptapeptide)
Fig. 1. A simplified representation of the kaliikrein-bradykinin system.
the breakdown of bradykinin into an inactive heptapeptide by
kininase II, which cleaves two amino acids from bradykinin's
C-terminal. In 1965, Ferreira discovered a series of compounds
that could inhibit this enzyme and thus potentiate the action of
bradykinin [31. Later Erdös and colleagues discovered that
kininase II was identical to the angiotensin-converting enzyme
that cleaves two amino acids from the C-terminal of the inactive
decapeptide angiotensin I to form the active octapeptide angio-
tensin II [4}. Since then, a series of bradykinin-potentiating
compounds have been isolated, characterized, and synthesized
in the laboratory; despite being bradykinin-potentiating agents
these substances became known as "ACE inhibitors." Newer
agents with the same pharmacodynamics but improved ancil-
lary properties (that is, kinetics, solubility, duration of action,
etc.) have been designed and now constitute a novel class of
drugs used widely in the treatment of hypertension and conges-
tive heart failure. Yet despite their well-documented dual
action, most of their effects have been attributed simply to the
inhibition of angiotensin II.
Although bradykinin is detectable in the circulation, it is
principally a tissue hormone with a widespread distribution, a
very short plasma half-life of less than one minute, and a variety
of direct and indirect local effects. Bradykinin's indirect effects
are mediated via stimulation of several autocrine and paracrine
factors. Among its well-documented effects are: increased
intestinal motility, vasodilation (indirect, when the endothelium
is intact), vasoconstriction (direct, when the endothelium is
damaged), stimulation of glucose uptake, stimulation of cate-
cholamine release from adrenal medulla and from sympathetic
nerve endings, stimulation of other tissue hormones (such as
prostaglandins, histamine, endothelium-derived relaxing fac-
tor), bronchoconstriction, inflammation with edema, and
heightened perception of pain.
The clinical relevance of bradykinin (BK) in various physio-
logic functions or morbid situations is still poorly understood.
Kinins have been implicated in the pathogenesis of endotoxic
shock, inflammation, edema, arthritis, colitis, carcinoid flush,
migraine, angina, hereditary angioedema, psoriasis, allergic
rhinitis, and asthma [5]. Bradykinin's actions are exerted via
activation of tissue receptors that have been classified by Regoli
and coworkers into two main types, B1 and B2 [6]. The B1
receptors, characterized by their selective sensitivity to the
agonist des-Arg9-BK and the antagonist des-Arg9-[Leu8]-BK,
are of low affinity; these receptors are coupled to adenylate
cyclase and use cAMP as the intracellular second messenger; in
contrast to B2 receptors, their function is independent of the
arachidonic acid cascade. The B1 receptors arise de novo
following tissue injury or under the influence of various agents,
mostly in damaged tissues, and are generated in particular by
endotoxin; shock ensues.
Most of the clinically relevant physiologic and pharmacologic
actions of bradykinin are mediated not by the B1 receptors,
however, but via the B2 receptors. The B2 receptors are stable
and of high affinity. Their excitation generates inositol phos-
phates as intracellular second messengers, coupling receptor
stimulation to Ca release in the cytosol; the action of the B2
receptors depends on activation of the arachidonic acid cascade
and generation of prostaglandins and therefore is subject to
blockade by cyclooxygenase inhibitors. Accumulated evidence
suggests that most of the clinically important effects of brady-
kinin are functions of the B2 receptors; these effects include the
vascular effects (that is, vasodilation and increased vascular
permeability), the metabolic effects (such as increased glucose
uptake by adipocytes and myocytes), the pain from stimulation
of sensory neurons, the release of histamine by mast cells, and
the release of catecholamines from sympathetic nerve terminals
(Table 2).
Measurements of circulating bradykinin levels in plasma have
given conflicting results, not only because of methodologic
difficulties but also because the hormone is probably inactivated
quite rapidly; therefore, its physiologic actions likely are ex-
erted only at the immediate site of its generation. The availabil-
ity of antagonists for the B2 receptors of bradykinin, first
synthesized by Vavrek and Stewart in the mid l980s [7], greatly
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Table 2. Effects of bradykinin
Action Clinical manifestation
B1 receptors
Smooth muscle constriction Endotoxic shock
and relaxation
B2 receptors
Release of autocrine-paracrine Vasodilation, tissue perfusion
factors (EDRF, PGs)
Vascular muscle relaxation
Increased vascular Angioedema, inflammatory
permeability edema
Release of histamine from
mast cells
Tissue inflammation Arthritis, colitis, pancreatitis
Sensory neuron stimulation Pain (bum blisters, angina,
(nociception) arthropathies)
Sympathetic nerve ending Catecholamine release
excitation (arrhythmogenic action)
Increased glucose transport Increased insulin sensitivity,
across cell membranes improved glucose tolerance
Sensitization of airways to Cough, bronchoconstriction,
irritants allergic rhinitis, asthma
enhanced research on the cardiovascular and other effects of
bradykinin. Using such a bradykinin antagonist, we demon-
strated that approximately 30% of the blood-pressure-lowering
effect of ACE inhibition in an experimental model of renovas-
cular hypertension was due to bradykinin [8]. These findings
have been confirmed and amplified by several other investiga-
tors using a variety of bradykinin antagonists [9, 10]. We
showed that infusion of a bradykinin antagonist failed to change
blood pressure in normotensive animals [11] unless the animals
had been previously nephrectomized or pretreated with the
cyclooxygenase inhibitor indomethacin [12, 13]. These findings
are in keeping with the knowledge that bradykinin's effects
depend in part on mobilization of the arachidonic acid cascade
and generation of prostaglandins [14]. This relationship is
particularly evident in the renal actions of endogenous brady-
kinin [15].
Infusion of exogenous bradykinin produces widespread vaso-
dilation, but this alteration reflects a pharmacologic effect
rather than the physiologic action of endogenous bradykinin.
Studies using a bradykinin antagonist demonstrated that endo-
genous bradykinin contributes to regulation of renal blood flow,
glomerular filtration, and salt and water excretion. In sodium-
depleted dogs, a kinin antagonist partially blocked the effect of
enalaprilat on renal blood flow [16]. Similar results have been
obtained in rabbits treated with captopril [17] and in rats treated
with an ACE inhibitor [18] or with a combination of ACE and
endopeptidase inhibitors [19]. Taken together, these data indi-
cate that when renal kinin generation is stimulated, kinins
contribute substantially to the regulation of renal blood flow.
Further experiments have indicated that intrarenal kinins are
more important in the regulation of papillary blood flow,
whereas cortical blood flow is more dependent on the renin-
angiotensin system [20]. Glomerular filtration rate also depends
to some extent on renal kinins; GFR diminished by 20% to 30%
after administration of a bradykinin antagonist [20, 21]. Finally,
bradykinin participates in the regulation of renal excretory
function by inhibiting sodium and water reabsorption in the
collecting tubule [22]. Thus, it contributes to the slight diuretic
and natriuretic action of ACE inhibitors, as indicated by the
antinatriuretic effect of bradykinin antibodies. In fact, data
suggest that bradykinin also acts as a mediator of the vasode-
pressor/natriuretic action of the atrial natriuretic peptide
(ANP). Inhibition of the neutral endopeptidase 24.11, which
also catabolizes ANP, potentiates the renal actions of ANP.
This effect could be abolished by a bradykinin antagonist; the
accumulation of bradykinin thus might have accentuated the
diuresis/natriuresis in this setting [23].
Recently, we assessed the relative contribution of bradykinin
to the maintenance of the normal vascular tone of various
organs by comparing regional blood flows in control rats and
rats treated with a bradykinin antagonist [24]. We found signif-
icant decreases in the regional blood flow of the coronary and
renal vasculature as well as in that of abdominal viscera, but we
discerned no change in the blood flow of the musculocutaneous
tissues (Fig. 2). With the exception of the effect on the cerebral
and splanchnic vasculature, the pattern of regional hemody-
namic effects of bradykinin inhibition was almost the opposite,
qualitatively, of that obtained after ACE inhibition [25]. Quan-
titatively, however, the changes produced by bradykinin inhi-
bition were less pronounced. This finding further corroborates
the concept that part of the regional vascular effects of so-called
ACE inhibition should be attributed to the generation of brady-
kinin. In general, it appears that the same vascular beds that are
preferentially sensitive to the constrictor effects of angiotensin
II are also the most sensitive to the vasodilatory action of
bradykinin. Two notable exceptions are the splanchnic vascu-
lature, which is sensitive to bradykinin only, and the cerebral
vasculature, which is highly sensitive to the vasoconstrictor
effect of angiotensin but not to the vasodilatory action of
braclykinin (although the cerebral vasculature does vasodilate in
response to prostaglandins [24, 26]). One possible explanation
for bradykinin's lack of effect on the cerebral vasculature is that
the substance might not be able to cross the blood-brain barrier
[27].
Bradykinin's effects on the heart are of particular interest. In
addition to its coronary dilating effect [28, 29], bradykinin can
exert other local actions on the myocardium, including an
anti-arrhythmogenic influence [301 and a metabolic action. The
latter—that is, increased glucose uptake by myocytes [31]—
perhaps may be relevant to the survival of myocardial cells
under conditions of acute or chronic ischemia. The cardiopro-
tective potential of ACE inhibition in the treatment of hyper-
tension and congestive heart failure is being increasingly rec-
ognized. Experimental and clinical evidence suggests that ACE
inhibitors afford protection of the ischemic or injured myocar-
dium from further anatomic and metabolic deterioration. The
notion that ACE inhibition also can offer primary protection of
the healthy myocardium in essential hypertension (by influenc-
ing coronary risk factors such as atherosclerosis, insulin resis-
tance, left-ventricular hypertrophy, etc.) is still speculative but
seems justified on the basis of existing knowledge. We recently
have reviewed the data in support of this notion elsewhere [321;
the evidence is good that these effects are partly attributable to
generation of bradykinin as well as to withdrawal of angiotensin
II. For example, several studies have shown that the myocar-
dial damage sustained during the repel-fusion phase following
acute myocardial ischemia—that is, myocardial "stunning" and
malignant ventricular arrhythmias—can be partly prevented by
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the concurrent administration of various ACE inhibitors [33]. A
biochemical marker of tissue injury after myocardial infarction
and subsequent reperfusion is the concentration of cellular
enzymes and constituents, such as creatine phosphokinase
(CPK) and purines, in the effluent. In one such experiment, pigs
were subjected first to coronary occlusion for 45 minutes and
then to reperfusion [34]. In comparison with untreated animals,
the pigs pretreated with an ACE inhibitor had a significantly
lower concentration of purines (a marker of the extent of
isehemia) and catecholamines. Lower levels of CPK, a marker
of irreversible cell damage, also were apparent (Fig. 3). Fur-
thermore, the surviving myocardium in the treated animals
displayed better electrophysiologic stability with a diminished
propensity for induction of ventricular arrhythmias. Similar
0
0 60 120 180 240 300 360
occlusion time (mm)
Fig. 3. Time course of creatine phosphokinase (CPK) levels in arterial
blood before, during, and after myocardial ischemia in pigs pretreated
with the ACE inhibitor zofenopril, compared with control animals
(mean + SEM, *D < 0.05). The lower CPK levels in treated animals
reflect less cellular damage or death. (Reproduced from Ref. 34 with
permission.)
observations were made in isolated perfused heart prepara-
tions, but in those experiments all the observed benefits of ACE
inhibition could be partially reversed or abolished by infusion of
a bradykinin antagonist [35]. The salutary effects of ACE
inhibition thus were attributable to a large extent to potentiation
of bradykinin rather than to blockade of angiotensin II.
The only way to separate the effects of angiotensin II
blockade per se from those of bradykinin potentiation is via a
direct comparison between the effects of ACE inhibition and
the effects of specific angiotensin II inhibition using, for exam-
ple, a selective competitive angiotensin II receptor antagonist
[36]. We recently compared systemic and regional hemodynam-
ics in rats with two-kidney, one-clip renovascular hypertension
after treatment with enalapril or DuP 753, an angiotensin II
receptor antagonist [37]. In this "high-renin" model, the results
of the two treatments were almost identical: both agents pro-
duced similar decreases in systemic blood pressure and vascu-
lar resistance and in the local vascular resistance of the same
organs, most notably in the renal vasculature of the intact
kidney. No differences were found in the organs known to have
differential sensitivity to angiotensin II and bradykinin. Thus, in
the setting of high-renin, high-angiotensin hypertension, angio-
tensin withdrawal is apparently the predominant mechanism of
action of ACE inhibition on hemodynamics.
Bradykinin might be responsible for certain beneficial meta-
bolic effects of ACE inhibition. Several studies have indicated
that essential hypertension is associated with some degree of
insulin resistance, as indicated by the elevated levels of insulin
and glucose in such patients, as compared with insulin and
glucose levels in normotensive subjects [38]. In patients with
the so-called "syndrome X," hypertension is associated not
only with insulin resistance, hyperinsulinemia, and glucose
intolerance (ranging from elevated postprandial glucose levels
to clinical type-Il diabetes mellitus), but also with dyslipidemia
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Fig. 2. Comparison of regional blood flows in various organs of
normal conscious rats treated with a bradykinin antagonist (BKA) or
vehicle (5% dextrose). The significantly diminished regional blood flow
to the kidneys, heart, and some abdominal viscera reflects the contri-
bution of bradykinin to the resting vascular tone of these organs.
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(elevated total and LDL cholesterol and/or triglycerides with
suppressed HDL) and increased visceral adiposity (the so-
called "apple shape") [39, 401. Patients with this syndrome,
considered by some to be a distinct nosologic entity, comprise
a sizable subgroup in the population of patients with essential
hypertension. Although the exact pathogenetic mechanism that
links these disorders with high blood pressure is poorly under-
stood and still under debate, maneuvers that improve glucose
tolerance and diminish insulin resistance (such as weight loss
and exercise) are known to also have a definite, although
modest, blood-pressure-lowering effect.
Many investigators believe that the failure of antihyperten-
sive medications to reduce the risk of coronary disease in
treated hypertensive patients to the same extent that such
agents reduce the risk of stroke, renal failure, and heart failure
might be due to the fact that the various components of
syndrome X act independently as coronary risk factors. If this
is so, treating one component—the elevated blood pressure—
would not suffice to eliminate the risk.
Treatment with thiazide diuretics or beta-adrenergic receptor
antagonists further accentuates the insulin resistance, as indi-
cated by the high incidence of hyperinsulinemia and hypergly-
cemia in patients treated with these agents. On the contrary,
treatment with ACE inhibitors diminishes insulin resistance and
improves tolerance to a glucose load [411, despite the fact that
angiotensin II has no known effect on glucose metabolism. As I
mentioned earlier, however, bradykinin stimulates glucose up-
take by myocytes [31]. The salutary effect of ACE inhibitors on
glucose metabolism is therefore attributable to the potentiation
of bradykinin; this effect most probably is mediated via pros-
taglandins [421.
Bradykinin also might be responsible for some of the unde-
sirable side effects of ACE inhibitors [43, 44]. The most
common sequela of ACE inhibitors is a ticklish, dry cough,
which ranges in prevalence from 8% to 25% according to
various reports. The effect varies according to age, race, and
gender: older and female patients are more likely to be affected
than are younger patients and males; Asians seem to be the
most sensitive, whites less so, and blacks the least (personal
observations).
Bradykinin's potent bronchoconstrictor effect is attributed to
stimulation of pulmonary sensory nerve endings and is medi-
ated in part via the release of prostanoids [45]. Inhalation of
bradykinin lowers the threshold of irritability of the airways to
noxious stimulants. Inhalation of a bradykinin antagonist ele-
vated this threshold, blocked allergen-induced bronchocon-
striction in a sheep model [46], and diminished the inflammatory
cell influx in the bronchoalveolar lavage of these animals [47].
Several bradykinin antagonists currently are under investiga-
tion for their potential to diminish the heightened airway
irritability caused by ACE inhibitors, but no results of human
studies are yet available.
Angioedema is an extremely rare but potentially severe
adverse reaction that has been observed with most ACE
inhibitors, perhaps due to bradykinin generation. Bradykinin is
known to be a mediator of inflammation, pain, and edema.
Injection of carrageenan into the paws of animals causes edema
and inflammation and is associated with an increased concen-
tration of kinins locally [48]. Topical application of a bradykinin
antagonist decreases inflammation in such animals [49]. In
humans, bradykinin antagonists diminish the pain of the ex-
posed burn blister bases [50]. Bradykinin increases vascular
permeability in tissues, and some bradykinin antagonists
blocked bradykinin-induced extravasation of fluid in rabbits
[51]. However, other such compounds act as "superagonists"
of bradykinin by stimulating the release of histamine from skin
mast cells [52, 531. It is also possible that cutaneous vascular
bradykinin receptors have species specificity [54]. The rele-
vance of these data to human ACE inhibition-induced angio-
edema remains speculative.
In summary, a great deal of experimental evidence suggests
that part of the benefits, and possibly some of the adverse
effects, of ACE inhibitors are attributable to the potentiation of
bradykinin. Most of this evidence is based on results obtained
with bradykinin analogues that have B2 receptor antagonistic
properties in isolated perfused tissue preparations and in ani-
mals pretreated with ACE inhibitors. Thus far, a similar role for
bradykinin in humans treated with ACE inhibitors has not been
established.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Masssachusetts): With
regard to the role of bradykinin in mediating part of the
vasodilating effect of ACE inhibitors, I would like to ask
whether appropriate maneuvers have been used to examine the
potential participation of endothelium-derived relaxing factor
(EDRF) in this phenomenon. Also, if indeed prostaglandins are
playing an important role, to what extent might the administra-
tion of nonsteroidal antiinflammatory drugs limit the beneficial
effects of ACE inhibition?
DR. GAVRAS: It is well established that bradykinin is an
endothelium-dependent vasodilator, the action of which is
mediated via release of EDRF [551. Indeed, the direct effect of
bradykinin when the endothelium is damaged is vasoconstric-
tion. In atherosclerotic vessels, in which the endothelium has
been covered by atherosclerotic plaques, bradykinin tends to
cause vasoconstriction too, because the release of EDRF is
impaired. It is only with intact endothelium that bradykinin
becomes a vasodilator, and then mainly through its action on
EDRF.
We gave bradykinin antagonists to rats and measured re-
gional blood flows. We then compared these changes in blood
flow with the changes that occurred with NGmonomethylL
arginine (L-NMMA), a blocker of the synthesis of EDRF and
with bradykinin plus L-NMMA. The patterns of vascular sen-
sitivity to EDRF and to bradykinin are very similar because the
changes in regional blood flow after bradykinin inhibition alone
were similar to those after EDRF inhibition [56]. That is, there
was a significant decrease in regional blood flows to the same
vascular beds, most notably the cardiac and renal circulation.
The combination of a bradykinin antagonist with the EDRF
inhibitor did not produce additional systemic or regional hemo-
dynamic changes compared with those obtained with either one
alone. In most organs, indomethacin produces a similar pattern,
but with one major difference: the brain's circulation is very
sensitive to prostaglandins but not to bradykinin, so indometh-
acm can change the cerebral circulation whereas bradykinin
cannot. Although ACE inhibition increases cerebral circulation,
this is not a bradykinin-mediated effect. It is, however, a
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prostaglandin-mediated effect, and that brings me to your
second question.
For years we believed that if we treated a patient with an
ACE inhibitor and gave indomethacin at the same time, we
would risk reversing some of the benefits of ACE inhibition. In
practice that has not occurred in the majority of patieilts, except
in those with moderate or severe renal failure and in elderly,
usually female, frail patients whose renal function is borderline
or mildy impaired. This phenomenon has been shown repeat-
edly in elderly women with arthritis who take indomethacin
intermittently. Their BUN and creatinine levels rise when they
receive indomethacin but fall when the drug is stopped; the
same is true of the blood-pressure-lowering effect. But this is a
small group of patients. I know of no study quantitating this
effect, but only in this small minority is the effect of nonsteroi-
dal antiinflammatory agents clinically relevant.
DR. MADIAs: I would like to return to your statement that all
ACE inhibitors appear to have the same attributes in terms of
potentiating the effects of bradykinin. Some authors have
claimed that at least the prostaglandin-stimulating effect of
various ACE inhibitors varies widely. Would you address this
issue in terms of bradykinin?
DR. GAVRAS: Any substance that can block kininase II should
potentiate bradykinin, so any ACE inhibitor would be a brady-
kinin-potentiating agent. But some researchers have suggested
that the various ACE inhibitors penetrate tissues to differing
degrees [573. As I said before, the circulating levels of brady-
kinin are not necessarily relevant for its functional activity
because it is degraded so fast; what really matters is its
concentration at the site of generation. If the ACE inhibitor has
a greater tissue penetration, it might be more effective in
potentiating bradykinin and prolonging its action locally. In
terms of the ACE inhibitors' ability in vitro to block kininase II,
it is the same for all of them, but their efficacy in blocking tissue
ACE activity varies. Some authors have suggested that the
sulfhydryl group, which is absent in most second-generation
ACE inhibitors, is the important component in terms of coro-
nary vasodilation. Studies compared ACE inhibitors with or
without the sulthydryl group in terms of their effect on the
coronary circulation 158]. The results suggest that even sulfhy-
dryl-containing compounds devoid of ACE-inhibiting capacity
produce an early increase in coronary flow, but a non-sulthy-
dryl ACE inhibitor, such as ramipril, produces a slower sus-
tained increase. Ramipril is the most potent of the currently
available ACE inhibitors, and this is most likely because it
penetrates tissue better.
DR. PEDRO PONCE (StaffNephrologist, Hospital de S. Cruz,
Lisbon, Portugal): You said that ACE inhibitors reverse insulin
resistance and improve cellular uptake of glucose. Also, we
know that ACE inhibitors retard the renal excretion of potas-
sium, Do you think that the mild hyperkalemic effect of ACE
inhibition can in part be counterbalanced in some patients by an
effect on internal balance, that is, by promoting cellular potas-
sium uptake secondary to reversal of insulin resistance?
DR. GAVRAS: Everybody measures extracelluar potassium,
but I'm not aware of any study measuring it intracellularly. This
is a good question, but I don't know the answer. I can tell you
though that most of the studies I showed were done in normal
people and normal animals, without any renal impairment, in
whom there should be no significant changes in potassium
balance. Besides, the secretion of aldosterone is driven not only
by angiotensin but also by ACTH, and this mechanism is not
affected by ACE inhibition.
DR. MADIAs: To my knowledge, all studies that have been
carried out in patients with essential hypertension, obesity, or
non-insulin-dependent diabetes mellitus have shown that the
prevailing insulin resistance to glucose uptake does not extend
to other biologic effects of the hormone, including potassium
uptake, lipolysis, and suppression of hepatic glucose output.
DR. ANDRE WEIGERT (Chief Resident in Internal Medicine,
Baylor College of Medicine, Houston, Texas): Feletou and
Vanhoutte noted that studies in which nitric oxide synthesis
was blocked with L-arginine analogues revealed that bradykinin
induced the release of an endothelial-derived factor and caused
prolonged cell hyperpolarization [59]; this effect was docu-
mented in micropuncture studies using a single smooth muscle
cell microelectrode [60]. Further, these researchers showed
that ACE inhibitors potentiate this L-arginine-resistant endo-
thelium-derived relaxation and hyperpolarization response to
bradykinin. Would you comment on the bradykinin-induced
non-nitric oxide EDRFs?
Da. GAVRAS: Many endothelium-derived relaxing factors
other than nitric oxide exist, although most people believe that
nitric oxide is the most important. I don't know whether anyone
has tried to separate the effects of bradykinin-mediated release
of these other EDRFs. But what is probably more interesting is
to try to separate the bradykinin-mediated effects from the
angiotensin Il-mediated effects of ACE inhibition. The only
way to do this is to compare the effects of ACE inhibition with
those of a direct angiotensin II antagonist. One such antagonist
was synthesized by Du Pont (DuP 753); this compound blocks
angiotensin II without affecting bradykinin or other paracrine or
autocrine factors.
DR. MADIAs: Is hypertension a bradykinin-deficient state?
DR. GAVRAS: It is tempting to speculate that some types of
hypertension are due to an imbalance between vasopressor/
antinatriuretic and vasodepressor/natriuretic factors. Some
studies have reported diminished urinary excretion of kallikrein
in certain hypertensive patients, which could imply a less active
kinin system in these individuals.
DR. JAIME MOREIRA (Staff Nephrolo gist, Hospital Curry,
Cabral, Lisbon): Is there any evidence that bradykinin induces
a change of the calcium levels in smooth muscle cells of the
vascular walls?
DR. GAVRAS: The B2 receptors use as second messenger
phosphatidyl inositol, which opens the calcium channels; so B2
receptor action is mediated by calcium and is thus unlike the
action of B1 receptors, which utilize adenylate cyclase as
second messenger. So, yes, calcium plays a role.
DR. MOREIRA: Does calcium's mediating role in this regard
have any implication for the use of calcium-channel-blockers in
therapy for hypertension?
DR. GAVRAS: That is a good question. I don't know whether
anybody has investigated a possible connection between bra-
dykinin and calcium antagonists.
DR. MADIAS: Do components of the kallikrein-bradykinin
system adjust after ACE inhibition? That is, does kininogen
change or do bradykinin receptors down-regulate? Given the
problems associated with measuring and interpreting circulating
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bradykinin levels in plasma, have molecular biologic techniques
been used in studying the system at the tissue level?
DR. GAVRAS: The bradykinin receptors have been character-
ized recently and they also have been cloned, but studies
employing the techniques of molecular biology have not yet
examined changes in the kallikrein-bradykinin system after
ACE inhibition. I don't know exactly what happens to the
levels of kininogen either, but we know what happens to the
levels of angiotensin II and aldosterone. In the long run, these
levels tend to return to baseline, and yet the blood-pressure-
lowering effect and all the hemodynamic effects of ACE inhibi-
tion are maintained.
DR. PEDRO NEVES (Staff Nephrologist, Hospital de Faro,
Faro, Portugal): We know that ACE inhibitors are also effec-
tive in the treatment of low-renin hypertension. But the activity
of all ACE inhibitors in vivo is not equal. Do you recommend
some ACE inhibitors more than others in the treatment of
low-renin hypertension?
DR. GAVRAS: The patient presented today had low-renin
hypertension, and the ACE inhibitor I used was captopril. I
don't know of any clinical studies designed to demonstrate
whether one ACE inhibitor is more effective than another.
Theoretically, it is possible that a more lipid-soluble compound,
like ramipril, better penetrates the central nervous system and
affects to a greater extent angiotensin II in brain tissues, and
therefore is more effective in low-renin hypertension. In exper-
imental studies some ACE inhibitors are more potent than
others but the final effect is the same, although some require
higher doses than the others. In practice any patient that
responds to one ACE inhibitor will respond to an equipotent
dose of another, and the same applies for those resistant to
ACE inhibition. Interestingly, the same is true for the "class"
side effects—anyone who develops a cough, for example, with
one ACE inhibitor will develop a cough with all the others.
This, of course, does not apply to allergic-type reactions such
as rash or itch.
DR. MADIAs: An extreme low-renin state is the anephric
state, and some data indicate that ACE inhibitors can produce
substantial decreases in blood pressure in anephric patients
[61]. Are there studies on the kinin system in anephric humans
or animals given ACE inhibitors?
DR. GAVRAS: I don't know of any studies measuring brady-
kinin levels in such patients. I do know, however, that ACE
inhibition works even in patients with primary hyperaldoster-
onism, again, an extreme example of low-renin hypertension. It
may have to do with the tissue renin-angiotensin system, that is,
the tissue penetrance of various ACE inhibitors and their ability
to inhibit locally the renin-angiotensin system.
DR. PONCE: Today's patient had low-renin hypertension and
a good response to captopril. Patients who don't respond to
ACE inhibition can be considered resistant both to angiotensin
II inhibition and to high levels of prostaglandins and bradykinin.
What's their problem?
DR. GAVRAS: In our hospital we see many black patients who
are resistant to ACE inhibition. Studies show that patients with
low-renin hypertension tend to also have diminished urinary
excretion of kallikrein, so their kallikrein-kinin system is much
less active. We can speculate that these patients with total
resistance to ACE inhibition are the ones who have the least
angiotensin-dependent hypertension and the most inactive kal-
likrein-kinin system too, so both these vasoactive systems are
unable to respond.
DR. MADIAS: I find it fascinating that the very enzyme that
converts angiotensin Ito angiotensin II is the same enzyme that
degrades the vasodilator bradykinin. This dual action highlights
the complex interrelations among components of the many
existing vasoactive systems. From the evolutionary point of
view, do we know whether this enzyme exhibits such "dual
channel" properties in other species?
DR. GAVRAS: This is not unique for kininase II, as other
enzymes also metabolize different vasoactive hormones. For
example, the neutral endopeptidase 24.11 degrades both brady-
kinin and the atrial natriuretic factor. I suspect there must be
some teleologic reason why these systems are related. I
touched very briefly on the effects of bradykinin on the blood
flow in the lungs, and as you know the ACE is very much
concentrated in the lung circulation. Although I'm sure both
systems are related, I don't know of any data on the ontogenetic
evolution of the systems.
DR. MARTINS PRATA (Director, Department of Nephrology,
Hospital de S. Maria, Lisbon): I'd like to return to the topic of
patients who don't respond to ACE inhibitors and who have
low plasma renin activity. Don't you think that such patients
have a volume-dependent type of hypertension, and that if you
give them diuretics they will respond to ACE inhibition?
DR. GAVRAS: To answer the second part of your question
first: yes, anybody who has a partial response or no response
to ACE inhibition as monotherapy is likely to have a better
response to the combination of an ACE inhibitor with a
diuretic. However, if you give diuretics and the blood pressure
responds, that doesn't mean there was a volume overload. This
is an ongoing debate. As you know, one school believes in the
volume/vasoconstriction theory. I happen to belong to the other
school, which believes that there is no such thing as hyperten-
sion due to volume overload, that is, intra-arterial volume
overload, whether or not total extracellular fluid volume expan-
sion is present. A few years ago we did a series of studies in
which we gave anephric rats saline infusions in amounts several
times larger than their total blood volume. The blood pressure
did not increase even to the point at which the saline load
resulted in congestive heart failure; at that point, the blood
pressure actually decreased. I know it is a highly controversial
subject. Measurements of intravascular volume in patients with
low-renin hypertension have shown that these patients actually
have a contracted blood volume; the best example of this is the
elderly patients who have suppressed renin levels and a very
much diminished plasma volume. One of the characteristics of
old age is a decreased plasma volume, yet these patients have
high blood pressure and increased peripheral arterial resistance.
While the increased peripheral resistance might not be due to
the renin-angiotensin system, other vasoconstrictive systems,
for example, vasopressin, exist. The elderly also are known to
have elevated catecholamine levels, but again their sympathetic
system is not overactive; if anything, it is underactive, so we
don't know the whole story. Nevertheless, I believe that
hypertension is not a volume-overload state. It is the high
peripheral vascular resistance and not an increased volume that
causes the blood pressure to rise. Why, then, do thiazides and
other diuretics work? They immediately cause a decrease of
plasma volume, but after a while the patients reach a steady
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state, the plasma volume returns to baseline, and the diuretic's
main effect becomes a decrease in vascular resistance, possibly
aided by removal of sodium from the vascular wall.
DR. MADIAS: Given the clinical relevance of the various
properties of bradykinin that you cited, to what extent might
chronic inhibition of kininase II by ACE inhibitors be detrimen-
tal?
DR. GAVRAS: This is an interesting philosophic question, not
only in terms of bradykinin potentiation but also in terms of
chronic inhibition of the renin-angiotensin system. Do we need
angiotensin? It would appear that in today's society with
abundant salt supplies, humans can maintain effective circula-
tion even with a chronically impaired function of the renin-
angiotensin system.
DR. PITA NEGIAo (Staff Nephrologist, Hospital de S. Cruz,
Lisbon): Why did diuretics lower the blood pressure in the
patient presented today? Might it be because they decrease the
content of sodium in the smooth muscle cells of the arterial
wall?
DR. GAVRAS: I'm sure that that mechanism is one of the
reasons. Diuretics decrease the sodium content and, as you
know, sodium overload stimulates the sympathetic system. In
several studies in which salt-sensitive animals (such as the
DOCA-salt rats) were sodium overloaded, the blood pressure
rose and the sympathetic nervous system outflow increased
[62]. Diuretics, by removing sodium, decrease the sensitivity of
the vascular wall receptors to various vasoactive hormones, for
example, angiotensin II or alpha adrenergic agonists.
DR. NEGRAO: Do you mean that humans, like rats, can be
classified as salt-sensitive or salt-resistant?
DR. GAVRAS: It is well known that some people are more
salt-sensitive than others in terms of their blood pressure
response to a given salt load. For example, in the United States,
more than 50% of black hypertensives are salt-sensitive. Fur-
ther, some 25% of all normotensives and almost 40% of black
normotensives are also salt-sensitive; this phenomenon has
been attributed to genetic selection [63]. But lots of other
hormonal differences exist between black and white hyperten-
sive populations, one of which might be sensitivity to vasopres-
sin. It also has been shown that salt sensitivity increases with
age [63].
DR. MADIAS: Dr. Schrier, like prostaglandins, bradykinin
inhibits the hydro-osmotic effect of vasopressin. Might part of
the hyponatremia-correcting effect of ACE inhibition be de-
rived from the potentiation of this bradykinin effect?
DR. ROBERT W. SCHRIER (Chairman, Department of Medi-
cine, University of Colorado Health Sciences Center, Denver,
Colorado): In addition to decreasing angiotensin II generation,
the administration of ACE inhibitors might increase plasma
bradykinin, a potential inhibitor of vasopressin's action. Thus,
in patients with heart failure who are treated with an ACE
inhibitor, any improvement in water excretion and correction of
hyponatremia could be mediated in part by an increase in
bradykinin-mediated inhibition of vasopressin action and/or a
decrease in angiotensin Il-mediated stimulation of vasopressin
release. However, when we decreased cardiac afterload in
patients with heart failure with either ACE inhibition or hy-
dralazine, the improvement in water excretion was comparable
in both cases. We concluded from these observations that an
improvement in cardiac output with either an ACE inhibitor or
hydralazine causes a baroreceptor- or ventricular receptor-
mediated suppression of vasopressin. Hydralazine increases
angiotensin II activity and is not known to stimulate bradykinin,
so it appears that the predominant effect of ACE inhibition, as
well as of hydralazine—improving water excretion in heart
failure—is mediated by non-osmotic supppression of vasopres-
sin release as a consequence of a rise in cardiac output.
DR. MADIAS: The utilization of all these bradykinin inhibitors
for unmasking the effects of bradykinin rests with the belief that
they don't have intrinsic agonistic effects on the vasculature.
Has this issue been tested adequately?
DR. GAvRA5: Yes. All these antagonists have been tested and
most of them do not have any vascular effect of their own in the
usually effective doses. However, there are B2 receptors in
many other tissues, so that an antagonist in the vascular
receptors could be a partial agonist in another tissue. For
instance, some of these bradykinin antagonists that I discussed
are partial agonists in the sympatho-adrenal tissue, and they
cause a release of catecholamines, although not as much as
bradykinin itself does. In some other tissues, these bradykinin
antagonists actually act as superagonists: for example, they act
on skin mast cells to release histamine. Since they have a much
stronger histamine-releasing effect than does bradykinin itself,
they can be considered "superagonists."
Reprint requests to Dr. I. Gavras, Hypertension and Atherosclerosis
Section, Boston University School of Medicine, 80 East Concord
Street, Boston, Massachusetts 02118—2394, USA
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